FindTrial
Sign In

Changes in anti-SARS-CoV-2 antibody levels in response to COVID-19 vaccination

Changes in anti-SARS-CoV-2 antibody levels in response to COVID-19 vaccine in patients with inflammatory bowel disease

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0007311
Enrollment
200
Registered
2022-05-19
Start date
2022-01-26
Completion date
Unknown
Last updated
2022-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Keimyung University Dongsan Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients who will receive or have received a SARS-CoV-2 booster vaccine among IBD patients aged 20 to 80 years 2. Crohn's disease or ulcerative colitis patients who taking at least one of agents among 5-aminosalycylic acid (ASA), immunomodulatory agents, and biological agents (infliximab, vedolizumab, ustekinumab etc) 3. A person who has signed a written consent form after agreeing to the purpose and method of the clinical research

Exclusion criteria

Exclusion criteria: 1. Those who have passed the booster vaccination more than 12 months ago 2. Those who have been diagnosed with IBD and have used IBD medications for less 3 months 3. Those who have had surgery within 3 months at the time of registration 4. Those who do not agree to participate in the research

Design outcomes

Primary

MeasureTime frame
Antibody to SARS-CoV-2—

Secondary

MeasureTime frame
Vaccine related adverse events—

Countries

Korea, Republic of

Contacts

Public ContactJeongseok Kim

Keimyung University Dongsan Hospital

nobeldoc@gmail.com+82-53-258-7762

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026